Literature DB >> 1500218

Expression of p53 protein in cutaneous melanoma.

L A Akslen1, O Mørkve.   

Abstract

The purpose of the present study was to examine the expression of p53 protein in malignant melanomas of the nodular sub-type, with special reference to the role of p53 alterations in the development of metastases. Increased expression of p53 protein was found in 29 of 30 cases using PAb1801 monoclonal antibody (MAb) and flow-cytometric detection on archival material. A large proportion of the cells were positive in a majority of the cases. The level of expression was not correlated to DNA ploidy or to subsequent development of local metastases. However, a significant decrease in p53 protein expression was observed in metastatic lesions, as compared with the corresponding primary tumors. Our results indicate that p53 alterations may be an early event in melanoma development, since almost all cases were affected, and that metastatic spread appears to be parallelled by decreased p53 protein expression.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1500218     DOI: 10.1002/ijc.2910520104

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  10 in total

1.  Prognostic significance of regulators of cell cycle and apoptosis, p16(INK4a), p53, and bcl-2 in primary mucosal melanomas of the head and neck.

Authors:  Manju L Prasad; Snehal G Patel; Jatin P Shah; Stacy Hoshaw-Woodard; Klaus J Busam
Journal:  Head Neck Pathol       Date:  2011-12-13

2.  Cell growth and p53 expression in primary acquired melanosis and conjunctival melanoma.

Authors:  S Seregard
Journal:  J Clin Pathol       Date:  1996-04       Impact factor: 3.411

3.  Chromosome abnormalities in metastatic melanoma.

Authors:  S Rauth; A Green; L Bratescu; T K Das Gupta
Journal:  In Vitro Cell Dev Biol Anim       Date:  1994-02       Impact factor: 2.416

4.  Immunohistochemical detection of the p53 oncoprotein in tumours of melanocytic origin.

Authors:  M Yamamoto; H Takahashi
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

5.  Expression of the p53 protein in malignant melanomas as a prognostic indicator.

Authors:  M Yamamoto; H Takahashi; K Saitoh; T Horikoshi; M Takahashi
Journal:  Arch Dermatol Res       Date:  1995       Impact factor: 3.017

6.  Predominance of the metastatic phenotype in hybrids formed by fusion of mouse and human melanoma clones.

Authors:  K L van Golen; S Risin; A Staroselsky; D Berger; M A Tainsky; S Pathak; J E Price
Journal:  Clin Exp Metastasis       Date:  1996-03       Impact factor: 5.150

7.  Modulation of p53 activity by IkappaBalpha: evidence suggesting a common phylogeny between NF-kappaB and p53 transcription factors.

Authors:  David H Dreyfus; Masayuki Nagasawa; Erwin W Gelfand; Lucy Y Ghoda
Journal:  BMC Immunol       Date:  2005-06-21       Impact factor: 3.615

8.  Deletions of the region 17p11-13 in advanced melanoma revealed by cytogenetic analysis and fluorescence in situ hybridization.

Authors:  I Okamoto; H Pirc-Danoewinata; J Ackermann; J Drach; H Schlagbauer Wadl; B Jansen; K Wolff; H Pehamberger; C Marosi
Journal:  Br J Cancer       Date:  1999-01       Impact factor: 7.640

9.  p63 is an alternative p53 repressor in melanoma that confers chemoresistance and a poor prognosis.

Authors:  Rubeta N Matin; Anissa Chikh; Stephanie Law Pak Chong; David Mesher; Manuela Graf; Paolo Sanza'; Valentina Senatore; Maria Scatolini; Francesca Moretti; Irene M Leigh; Charlotte M Proby; Antonio Costanzo; Giovanna Chiorino; Rino Cerio; Catherine A Harwood; Daniele Bergamaschi
Journal:  J Exp Med       Date:  2013-02-18       Impact factor: 14.307

10.  TP53 allele loss, mutations and expression in malignant melanoma.

Authors:  V A Flørenes; T Oyjord; R Holm; M Skrede; A L Børresen; J M Nesland; O Fodstad
Journal:  Br J Cancer       Date:  1994-02       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.